236 related articles for article (PubMed ID: 20695833)
41. Preparation and in vitro evaluation of hydrophilic fenretinide nanoparticles.
Ledet GA; Graves RA; Glotser EY; Mandal TK; Bostanian LA
Int J Pharm; 2015 Feb; 479(2):329-37. PubMed ID: 25542987
[TBL] [Abstract][Full Text] [Related]
42. Preparation and physicochemical characteristics of polylactide microspheres of emamectin benzoate by modified solvent evaporation/extraction method.
Zhang SF; Chen PH; Zhang F; Yang YF; Liu DK; Wu G
J Agric Food Chem; 2013 Dec; 61(50):12219-25. PubMed ID: 24283703
[TBL] [Abstract][Full Text] [Related]
43. Long-term release of clodronate from biodegradable microspheres.
Perugini P; Genta I; Conti B; Modena T; Pavanetto F
AAPS PharmSciTech; 2001 Jul; 2(3):E10. PubMed ID: 14727869
[TBL] [Abstract][Full Text] [Related]
44. In vitro evaluation of suspoemulsions for in situ-forming polymeric microspheres and controlled release of progesterone.
Turino LN; Mariano RN; Mengatto LN; Luna JA
J Microencapsul; 2015; 32(6):538-46. PubMed ID: 26218541
[TBL] [Abstract][Full Text] [Related]
45. Preparation of protein loaded poly(D,L-lactide-co-glycolide) microparticles for the antigen delivery to dendritic cells using a static micromixer.
Wischke C; Lorenzen D; Zimmermann J; Borchert HH
Eur J Pharm Biopharm; 2006 Apr; 62(3):247-53. PubMed ID: 16288857
[TBL] [Abstract][Full Text] [Related]
46. Recent advances in the preparation progress of protein/peptide drug loaded PLA/PLGA microspheres.
Xu FH; Zhang Q
Yao Xue Xue Bao; 2007 Jan; 42(1):1-7. PubMed ID: 17520799
[TBL] [Abstract][Full Text] [Related]
47. β-methasone-containing biodegradable poly(lactide-co-glycolide) acid microspheres for intraarticular injection: effect of formulation parameters on characteristics and in vitro release.
Song X; Song SK; Zhao P; Wei LM; Jiao HS
Pharm Dev Technol; 2013; 18(5):1220-9. PubMed ID: 22295954
[TBL] [Abstract][Full Text] [Related]
48. Interpenetrating polymer network (IPN) hydrogel microspheres for oral controlled release application.
Banerjee S; Siddiqui L; Bhattacharya SS; Kaity S; Ghosh A; Chattopadhyay P; Pandey A; Singh L
Int J Biol Macromol; 2012 Jan; 50(1):198-206. PubMed ID: 22062120
[TBL] [Abstract][Full Text] [Related]
49. A novel sustained-release formulation of recombinant human growth hormone and its pharmacokinetic, pharmacodynamic and safety profiles.
Wei Y; Wang Y; Kang A; Wang W; Ho SV; Gao J; Ma G; Su Z
Mol Pharm; 2012 Jul; 9(7):2039-48. PubMed ID: 22663348
[TBL] [Abstract][Full Text] [Related]
50. The preparation and evaluation of poly(epsilon-caprolactone) microparticles containing both a lipophilic and a hydrophilic drug.
Hombreiro Pérez M; Zinutti C; Lamprecht A; Ubrich N; Astier A; Hoffman M; Bodmeier R; Maincent P
J Control Release; 2000 Apr; 65(3):429-38. PubMed ID: 10699300
[TBL] [Abstract][Full Text] [Related]
51. Poly (epsilon-caprolactone) microparticles containing Levobunolol HCl prepared by a multiple emulsion (W/O/W) solvent evaporation technique: effects of some formulation parameters on microparticle characteristics.
Karataş A; Sonakin O; Kiliçarslan M; Baykara T
J Microencapsul; 2009 Feb; 26(1):63-74. PubMed ID: 18608798
[TBL] [Abstract][Full Text] [Related]
52. Preparation and in vitro characterization of vascular endothelial growth factor (VEGF)-loaded poly(D,L-lactic-co-glycolic acid) microspheres using a double emulsion/solvent evaporation technique.
Karal-Yılmaz O; Serhatlı M; Baysal K; Baysal BM
J Microencapsul; 2011; 28(1):46-54. PubMed ID: 21171816
[TBL] [Abstract][Full Text] [Related]
53. The influence of spray-drying parameters on phase behavior, drug distribution, and in vitro release of injectable microspheres for sustained release.
Meeus J; Lenaerts M; Scurr DJ; Amssoms K; Davies MC; Roberts CJ; Van Den Mooter G
J Pharm Sci; 2015 Apr; 104(4):1451-60. PubMed ID: 25648704
[TBL] [Abstract][Full Text] [Related]
54. Preparation and in vitro release behaviour of 5-fluorouracil-loaded microspheres based on poly (L-lactide) and its carbonate copolymers.
Zhu KJ; Zhang JX; Wang C; Yasuda H; Ichimaru A; Yamamoto K
J Microencapsul; 2003; 20(6):731-43. PubMed ID: 14594662
[TBL] [Abstract][Full Text] [Related]
55. Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation.
Su ZX; Shi YN; Teng LS; Li X; Wang LX; Meng QF; Teng LR; Li YX
Pharm Dev Technol; 2011 Aug; 16(4):377-84. PubMed ID: 20370594
[TBL] [Abstract][Full Text] [Related]
56. Microsphere delivery of Risperidone as an alternative to combination therapy.
D'Souza S; Faraj J; DeLuca P
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):631-9. PubMed ID: 23892159
[TBL] [Abstract][Full Text] [Related]
57. Double-walled microspheres loaded with meglumine antimoniate: preparation, characterization and in vitro release study.
Navaei A; Rasoolian M; Momeni A; Emami S; Rafienia M
Drug Dev Ind Pharm; 2014 Jun; 40(6):701-10. PubMed ID: 23594302
[TBL] [Abstract][Full Text] [Related]
58. Using TEM to couple transient protein distribution and release for PLGA microparticles for potential use as vaccine delivery vehicles.
Zhao A; Rodgers VG
J Control Release; 2006 Jun; 113(1):15-22. PubMed ID: 16707186
[TBL] [Abstract][Full Text] [Related]
59. Impact of surfactant selection on the formulation and characterization of microparticles for pulmonary drug delivery.
Cocks E; Alpar O; Somavarapu S; Greenleaf D
Drug Dev Ind Pharm; 2015 Mar; 41(3):522-8. PubMed ID: 24650006
[TBL] [Abstract][Full Text] [Related]
60. Molecular mechanism of improved structural integrity of protein in polymer based microsphere delivery system.
Rawat S; Kohli N; Suri CR; Sahoo DK
Mol Pharm; 2012 Sep; 9(9):2403-14. PubMed ID: 22724678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
